Uniquity Bio Taps Jason Moore as New SVP of Regulatory & Quality

Why This Matters: See our coverage of other industry executive team appointments and promotions here.

Uniquity Bio announced it has named Jason Moore as Senior Vice President (SVP), Regulatory & Quality. A clinical-stage drug development company, Uniquity focuses on immunology and inflammation.

Moore most recently was SVP of Regulatory Affairs & Quality Assurance at Nefro Avillion Clinical Development. (This was previously Avillion Life Sciences, acquired by Nefro Health in 2025.) His appointment aligns with Uniquity’s push for potential late-stage development of solrikitug, its lead asset.

Solrikitug, a highly potent monoclonal antibody, targets thymic stromal lymphopoetin (TSLP). Topline data readouts are coming from Phase II trials in asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE).

SVP Brings Wide Experience

Moore gives Uniquity a seasoned biopharma executive who has led drug development programs in every stage and multiple therapeutic areas.

At Avillion, he oversaw successful clinical development and marketing applications for Airsupra, in partnership with AstraZeneca. Earlier employment includes JEM Biopharma Consulting, Camargo Pharmaceutical Services, PLx Pharma, and BioHouston.

“I’ve been impressed by the rigor that Uniquity’s team brings to all aspects of development,” Moore said. “I’m eager to contribute to that work as we move into a new stage. I look forward to building on the company’s strong regulatory and quality foundation to ensure excellence as we scale.”

More on Uniquity’s Plans

Solrikitug was in-licensed from Merck (known as MSD outside the United States and Canada). In addition to it, Uniquity is also actively seeking bispecific and/or combination products for clinical testing. The ultimate goal is to combine solrikitug with other key inflammatory targets, potentially enhancing efficacy and broadening applicable patient populations.